Clinical and epidemiological data for bone metastases

被引：1

作者：

Debiais, F. ^{[1
]}

机构：

[1] Univ Poitiers, CHU Poitiers, Serv Rhumatol, F-86021 Poitiers, France

来源：

ONCOLOGIE | 2015年 / 17卷 / 03期

关键词：

Bone metastasis; Epidemiology; Skeletal-related events; SKELETAL-RELATED EVENTS; BREAST-CANCER PATIENTS; LONG-TERM EFFICACY; PROGNOSTIC-FACTORS; ZOLEDRONIC ACID; SOLID TUMORS; COMPLICATIONS; MORTALITY; SURVIVAL; CARCINOMA;

D O I：

10.1007/s10269-015-2488-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bone is a frequent site for metastases in patients with advanced solid tumours, above all concerning prostate, breast, and lung cancers. Bone metastases are often responsible for pain and can be at the origin of skeletal-related events (SRE), associated with morbidity, decrease in quality of life and survival, highlighting the importance of a rapid diagnosis of cancer and treatment in case of bone metastases so as to decrease the risk of these complications.

引用

页码：63 / 68

页数：6

共 50 条

[1] Epidemiology and clinical features of bone metastases
Cvitkovic, Frederique
Mouret-Fourme, Emmanuelle
BULLETIN DU CANCER, 2013, 100 (11) : 1073 - 1081
[2] The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases
dos Reis Oliveira, Marcelo Braganca
de Queiroz Mello, Fernanda Carvalho
Machado Paschoal, Marcos Eduardo
LUNG CANCER, 2016, 96 : 19 - 24
[3] Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial
Gillespie, Erin F.
Yang, Joanna C.
Mathis, Noah J.
Marine, Catherine B.
White, Charlie
Zhang, Zhigang
Barker, Christopher A.
Kotecha, Rupesh
McIntosh, Alyson
Vaynrub, Max
Bartelstein, Meredith K.
Mitchell, Aaron
Guttmann, David M.
Yerramilli, Divya
Higginson, Daniel S.
Yamada, Yoshida J.
Kohutek, Zachary A.
Powell, Simon N.
Tsai, Jillian
Yang, Jonathan T.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (01) : 38 - +
[4] Epidemiology of bone metastases
Ryan, Casey
Stoltzfus, Kelsey C.
Horn, Samantha
Chen, Hanbo
Louie, Alexander V.
Lehrer, Eric J.
Trifiletti, Daniel M.
Fox, Edward J.
Abraham, John A.
Zaorsky, Nicholas G.
BONE, 2022, 158
[5] Clinical landscape of cancer metastases
Riihimaeki, Matias
Thomsen, Hauke
Sundquist, Kristina
Sundquist, Jan
Hemminki, Kari
CANCER MEDICINE, 2018, 7 (11): : 5534 - 5542
[6] Skeletal-related Events and Clinical Outcomes in Patients with Bone Metastases and Normal Levels of Osteolysis: Exploratory Analyses
Lipton, A.
Cook, R.
Brown, J.
Body, J. J.
Smith, M.
Coleman, R.
CLINICAL ONCOLOGY, 2013, 25 (04) : 217 - 226
[7] Bone markers for monitoring efficacy in patients with bone metastases receiving zoledronic acid: a review of published data
Huang, Qian
Ouyang, Xuenong
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2013, 28 (03) : 242 - 248
[8] Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology
Vogel, Theresa
Wendler, Julia
Frank-Raue, Karin
Kreissl, Michael C.
Spitzweg, Christine
Fassnacht, Martin
Raue, Friedhelm
Kroiss, Matthias
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (06) : E2239 - E2246
[9] Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents
Lipton, Allan
Smith, Matthew R.
Fizazi, Karim
Stopeck, Alison T.
Henry, David
Brown, Janet E.
Shore, Neal D.
Saad, Fred
Spencer, Andrew
Zhu, Li
Warner, Douglas J.
CLINICAL CANCER RESEARCH, 2016, 22 (23) : 5713 - 5721
[10] Incidence and consequences of bone metastases in lung cancer patients
Kuchuk, Michael
Addison, Christina L.
Clemons, Mark
Kuchuk, Iryna
Wheatley-Price, Paul
JOURNAL OF BONE ONCOLOGY, 2013, 2 (01) : 22 - 29

← 1 2 3 4 5 →